Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86

YC and XSX have applied for a provisional patent for a series of antibodies, which includes BD55–5514 (SA55) used as a standard monoclonal IgA antibody in this study; they are also the founders of Singlomics Biopharmaceuticals. YC, XSX, LH, HM, and QP-H filed a US patent on the use of secretory IgA antibodies for therapy against SARS-CoV-2 (Secretory IgA Antibodies Against COVID Infection). All other authors declare no competing interests. This work was supported by the EU Horizon 2020 Research and Innovation Program (ATAC, 101003650; awarded to MH, DFR, LH, HM, and QP-H), the Swedish Research Council (2019-01302 and 2020-06116, awarded to QP-H), the Knut and Alice Wallenberg Foundation (KAW2020.0102, awarded to LH and QP-H), the Petrus och Augusta Hedlunds stiftelse (awarded to HM and FZ), the Stiftelsen Clas Groschinskys Minnesfond (awarded to HM and FZ), the Magnus Bergvalls Stiftelse (awarded to FZ), and the Eva & Oscar Ahréns Stiftelse (awarded to FZ). LH, HM, and QP-H are joint last authors.